Clinical Trials

January 22, 2013

A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endotherlial Dysfunction in Pulmonary Arterial Hypertension

  • Study Sponsor: National Institutes of Health
  • Start Date: 01/2013
  • End Date: 01/2016
  • Design: Placebo-controlled (Randomized), background treatment allowed
  • Age range (years): from 18 to 99
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • Heritable - APAH
    • CTD - APAH
    • CHD - APAH
    • PoPH - APAH
    • Toxic - APAH
    • HIV - APAH
    • Hem - APAH
  • Study Duration for individual patient: 24 weeks
  • Contact: Bonnie Harper at 
  • Listing on


FacebookTwitterInstagram iconLinkedInYouTube

For optimal viewing of, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs. PHA does not endorse or recommend any commercial products or services.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2016 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.